Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Merck
Johnson and Johnson
Colorcon
Medtronic

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

TAKEDA Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for TAKEDA

Drugs and US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa COLCRYS colchicine TABLET;ORAL 022352-001 Jul 29, 2009 AB RX Yes Yes 8,440,721   Start Trial   Start Trial
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No 7,550,433   Start Trial   Start Trial
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 RX Yes No 8,173,663   Start Trial   Start Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 RX Yes No 7,807,689   Start Trial Y Y   Start Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes 8,722,684   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Na PREVACID lansoprazole FOR SUSPENSION, DELAYED RELEASE;ORAL 021281-001 May 3, 2001 5,013,743*PED   Start Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 6,303,661   Start Trial
Takeda Pharms Usa ACTOPLUS MET XR metformin hydrochloride; pioglitazone hydrochloride TABLET, EXTENDED RELEASE;ORAL 022024-001 May 12, 2009 6,495,162   Start Trial
Takeda Pharms Usa NESINA alogliptin benzoate TABLET;ORAL 022271-002 Jan 25, 2013 6,303,640   Start Trial
Takeda Pharms Usa KAZANO alogliptin benzoate; metformin hydrochloride TABLET;ORAL 203414-001 Jan 25, 2013 6,303,640   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TAKEDA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Pellets/Capsul 15 mg and 30 mg ➤ Subscribe 2005-12-05
➤ Subscribe Capsule 60 mg ➤ Subscribe 2010-08-25
➤ Subscribe Extended-release Tablets 15 mg/1000 mg and 30 mg/1000 mg ➤ Subscribe 2011-09-23
➤ Subscribe Tablets 0.6 mg ➤ Subscribe 2011-12-23
➤ Subscribe Tablets 12.5 mg/500 mg and 12.5 mg/1000 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 8 mg ➤ Subscribe 2009-07-22
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2013-02-13
➤ Subscribe Delayed-release Orally Disinte 15 mg and 30 mg ➤ Subscribe 2006-12-27
➤ Subscribe Delayed-release Capsule 30 mg ➤ Subscribe 2010-11-30
➤ Subscribe Tablets 15 mg/500 mg and 15 mg/850 mg ➤ Subscribe 2008-03-06
➤ Subscribe Tablets 30 mg/2 mg and 30 mg/4 mg ➤ Subscribe 2009-12-22
➤ Subscribe Tablets 6.25 mg, 12.5 mg and 25 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 5 mg, 10 mg, 15 mgand 20 mg ➤ Subscribe 2017-10-02

Supplementary Protection Certificates for TAKEDA Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1586571 2014/012 Ireland   Start Trial PRODUCT NAME: ALOGLIPTIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/844/001-027 20130919
1412357 PA2008013,C1412357 Lithuania   Start Trial PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REGISTRATION NO/DATE: EU/1/08/455/001 - EU/1/08/455/014 20080716
1261586 C01261586/02 Switzerland   Start Trial PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329
1412357 C 2008 016 Romania   Start Trial PRODUCT NAME: SITAGLIPTIN OPTIONAL SUB FORMA DE SARE ACCEPTABILAFARMACEUTIC IN SPECIAL MONOFOSFAT + METFORMIN OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC IN SPECIALCLORHIDRAT; NATIONAL AUTHORISATION NUMBER: RO EU/1/08/455/001 - RO EU/1/08/455/014; DATE OF NATIONAL AUTHORISATION: 20080716; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): CH 58450 01, CH 58450 02, CH 58450 03; DATE OF FIRST AUTHORISATION IN EEA: 20080408
1586571 CA 2014 00011 Denmark   Start Trial PRODUCT NAME: ALOGLIPTIN; REG. NO/DATE: EU/1/13/844/001-027 20130919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Colorcon
Johnson and Johnson
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.